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Background: Technological advances in DNA sequencing have made gene testing fast and affordable, but there
are challenges to the translation of these improvements for patient benefit. The Mainstreaming Cancer Genetics
(MCG) programme is exploiting advances in DNA sequencing to develop the infrastructure, processes and
capabilities required for cancer gene testing to become routinely available to all those that can benefit.
Methods: The MCG programme held a consultation day to discuss the development of cancer genetics with senior
representation from all 24 UK cancer genetic centres. The current service landscape and capacity for expansion was
assessed through structured questionnaires. Workshop discussion addressed the opportunities and challenges to
increasing cancer gene testing in the National Health Service (NHS).
Results: Services vary with respect to population served and models of service delivery, and with respect to methods
and thresholds for determining risk and testing eligibility. Almost all centres want to offer more cancer gene testing
(82%) and reported increasing demand for testing from non-genetic clinical colleagues (92%). Reported challenges to
increasing testing include the complexity of interpreting the resulting genetic data (79%), the level of funding
and complexity of commissioning (67%), the limited capacity of current processes and cross-disciplinary relationships
(38%), and workforce education (29%).
Conclusions: Priorities to address include the development and evaluation of models of increasing access to gene
testing, the optimal process for interpretation of large-scale genetic data, implementation of appropriate commissioning
and funding processes, and achieving national consistency. The UK cancer genetics community have high expertise and
strong commitment to maximising scientific advances for improved patient benefit and should be pivotally involved in
the implementation of increased cancer gene testing.Background
Healthcare services need to utilise advances in genomic
technology and knowledge for the benefit of patients.
This was a key theme of the 2003 Genetics White Paper
Our Inheritance, Our Future [1]. Since 2003 there has
been rapid, revolutionary development of genomic tech-
nologies and extensive advances in knowledge of the
impact of genomic variation on human disease. High-
throughput DNA sequencing and analysis have been
widely used in the research setting, but have not, thus* Correspondence: rahmanlab@icr.ac.uk
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provision in the National Health Service (NHS) [2,3]. The
House of Lords Genomic Medicine Report highlighted
this translational gap and began to define the challenges of
integrating genomic advances within the NHS [4]. How-
ever, despite 10 years of discussions there remains a lack
of clear operational direction regarding the implementa-
tion of increased gene testing within healthcare services.
In the UK, specialist genetic services, including cancer
genetics, are organised regionally and delivered by con-
sultant clinical geneticists and genetic counsellors [5].
Cancer genetics offers services to individuals and fam-
ilies with the goal of assisting treatment decisions in pa-
tients with cancer and facilitating early cancer detection
and cancer prevention in their relatives. This includes
cancer risk estimation, gene testing, assistance withhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Slade et al. Genome Medicine  (2015) 7:18 Page 2 of 6decisions on treatment options, referral for cancer sur-
veillance and discussion of cancer risk-reducing options.
Mutations of over 100 genes are known to cause an in-
creased risk of cancer and these underlie approximately
3% of cancer overall, though the contribution to individ-
ual cancers varies widely, with substantial contribution
to some cancers such as childhood embryonal tumours,
ovarian cancer and certain endocrine cancers [6]. Fur-
thermore there is increasing evidence that identification
of cancer predisposition gene mutations has an impact
on improved diagnosis and management of cancer patients
and their families [6].
A large proportion of the work of any cancer genetic
service is the management of familial breast and ovarian
cancer, and this clinical area exemplifies both the oppor-
tunities and challenges to increasing access to gene
testing. Management of familial breast cancer is one of
the few areas of clinical genetic practice with National
Institute of Health and Care Excellence (NICE) Guidance
[7]. Mutations in BRCA1 and BRCA2 underlie a propor-
tion of breast and ovarian cancer and the most recent
guidelines for familial breast cancer, updated in 2013,
recommend testing individuals at ≥10% chance of having
a mutation [7,8]. Studies have shown that approximately
15% of high-grade serous ovarian cancer is due to muta-
tions in BRCA1 or BRCA2 [9,10]. Importantly, about half
of the mutation-positive patients do not report a signifi-
cant family history of cancer [9]. Although eligible for test-
ing at the current risk threshold, rate of referral of ovarian
cancer patients to clinical genetics is low, reported to be
only 7% to 20% [9,10]. In addition to the inequity com-
pared to familial breast cancer, important opportunities
for improved management of ovarian cancer patients and
cancer prevention in their relatives are being lost. The
current model of specialised service delivery, with limited
staff numbers, inflexible infrastructure and specialised
commissioning, lacks the capacity to accommodate this
unmet obligation, or to address increasing demand for
cancer gene testing more generally.
The Wellcome Trust Mainstreaming Cancer Genetics
(MCG) programme [11] is a cross-disciplinary, transla-
tional initiative that aims to develop the assays, inform-
atics, clinical infrastructure, education and evaluation
that will allow implementation of gene testing into rou-
tine clinical care of cancer patients and their relatives.
The programme aims to provide scalable and transfer-
able tools for the integration of gene testing into main-
stream medical practice across the NHS [12]. The MCG
programme hosted a consultation day in July 2013, to
inform the development of its implementation models.
The consultation included senior clinical representatives
from all 24 cancer genetic services across the UK. The
list of cancer genetic services represented is given in
Additional file 1: Table S1.Methods
Selection of consultation representatives
A list of all UK cancer genetic services was compiled
using information available on the British Society for
Genetic Medicine (BSGM) website [13]. A total of 24
UK cancer genetic services were identified. All the can-
cer genetic leads from these services were contacted and
invited to attend the consultation event, or to nominate
a senior representative of their service if they were
personally unable to attend. All services invited agreed
to attend. The attendees were sent two pre-consultation
questionnaires to complete prior to the event. We encour-
aged the attendees to discuss and answer the question-
naires with their colleagues, so that the answers were
representative of their service. All attendees at the consult-
ation event participated in the workshop discussions. It
was agreed that individual responses would be kept
confidential to ensure representatives could respond freely.
Pre-consultation questionnaires
Two structured questionnaires were sent by email to
each attendee prior to the day. The Service question-
naire focused on the current landscape of cancer genetic
services (Additional file 2: Table S2). The Implementa-
tion questionnaire addressed attitudes and capacity for
evolution of services (Additional file 3: Table S3). The
questions in the pre-consultation questionnaires were
selected, after detailed discussions, by five members of
the MCG programme team (IS, DR, CT, HH and NR)
informed by their extensive experience of the field and
the engagement activities of the MCG programme.
Multiple choice and discrete answers from the question-
naires were collated directly; free text responses were
independently curated by two MCG programme mem-
bers (IS and DR) and then collated.
Focused workshop discussion
The consultation day included three focused workshop
discussions. Each workshop addressed a defined ques-
tion: (1) How can we provide equitable gene testing to
ovarian patients and their families? (2) How can we en-
sure variants are interpreted and managed appropriately?
(3) How can we implement consistent cancer genetic
care across UK? The topics were selected by five mem-
bers of the MCG programme team (IS, DR, CT, HH and
NR) after evaluation of the pre-consultation question-
naires to allow more focused, detailed discussions of the
areas causing biggest concern. The consultation day at-
tendees were divided into four groups, each with a facili-
tator (NR, IS, HH or CT) to discuss each question in
turn. This was to ensure opportunities for all attendees
to voice their opinions. The groups were organised such
that the location and size of services was evenly distributed.
After each workshop discussion the full group reconvened
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the question together. The outcomes of the workshop dis-
cussions were documented separately (NR, IS, HH or CT)
and reviewed and collated afterwards (IS and DR).
Notes of the full consultation day discussions and pre-
questionnaire data were documented and summarised
separately (IS and DR) and then collated and discussed
(IS, DR, CT, HH and NR).
Consultation report
Prior to writing the manuscript a summary of the con-
sultation outcomes was circulated to all the attendees
and also presented at the British Society for Genetic
Medicine conference, to ensure it was a fair and appro-
priate representation of the consultation discussions.
The manuscript was also circulated to the attendees. It
should be noted that this report is a summary of the
consultation and therefore does not necessarily represent
individual attendees’ or genetic centres’ viewpoints.
Results and discussion
Service and implementation questionnaires
Twenty-two responses were received for the service
questionnaire (92%). Twenty-four responses were received
for the implementation questionnaire (100%).
Overview of cancer genetic services
In the UK, cancer genetic centres provide a service for
populations between 475,000 to 5.4 million people. Each
centre works with between one and seven specialist
oncology centres in providing their service. All services
have a team of consultant cancer geneticists, specialist
registrars in training and genetic counsellors. Individual
centres differ with respect to the thresholds at which
testing for a BRCA1 or BRCA2 mutation is offered and
also in the methods used for determining risk. The risk
thresholds were in the range of 10% to 20%. Many differ-
ent methods for determining risk are currently used,
including local or multi-regional protocols based on
practical distillation of modelled data, for example, the
Marsden Protocol 2 [14] to genetic evaluation of each
patient by individual clinicians facilitated by tools such
as the Manchester scoring system and/or computer-
based algorithms such as BOADICEA [15].
Current capacity
Within their current service configuration 14% (3/22) of
centres said they were unable to offer testing to additional
people. Fifty-five percent (12/22) said they could accom-
modate moderate increase in testing; between 50 and
150 extra people per year. Twenty-seven percent (6/22)
responded that their current service could accommodate
testing >150 extra people per year. There was one non-
response.Individuals with high-grade serous ovarian cancer, with
or without a family history of breast or ovarian cancer
are at a greater than 10% risk of having a BRCA1 or
BRCA2 mutation [9,10]. In response to this evidence the
majority of UK cancer genetic centres (73%, 16/22) are
planning to at least offer testing to ovarian cancer patients
that are referred to their service. However, 27% (6/22) of
centres reported not being able to do so, all stating insuffi-
cient funding and/or staff as the reason.
One of the models proposed to increase gene testing is
for non-genetic specialist services to undertake testing
in eligible patients within their area of clinical expertise
[12]. Sixteen centres (73%, 16/22) reported that non-
geneticists within their region are already directly order-
ing specific tests, by local agreement. The majority of
this ‘mainstream’ delivery of cancer gene testing is for
RET testing by endocrinologists (36%, 8/22). BRCA1 and
BRCA2 testing by oncologists is occurring in three centres
(14% - including The Royal Marsden Hospital through an
implementation pilot of the MCG Programme - see [11]
for more details).
Future service expansion
The great majority of the UK cancer genetic centres,
82% (18/22, two non-responses), would like to be able to
offer more cancer gene testing. Moreover, 92% (22/24)
think there is/will be increasing interest from non-
genetic clinicians in their region for more cancer gene
testing in their patients. All centres believe there is/will
be increasing interest from patients and the public about
cancer gene testing.
Concerns and barriers
The greatest concern expressed about increasing gene
testing was the challenge of interpreting the increased
number of variants that would inevitably be identified.
Nineteen of the 24 centres (79%) highlighted this as a
concern. The second most commonly reported concern
was inadequate or mis-timed pre-test counselling of
patients (38%, 9/24).
Funding, both the level funding and the complexity
of commissioning was identified as the most signifi-
cant barrier to increasing gene testing, highlighted by
16/24 (67%) centres. Other barriers included the lim-
ited capacity of current processes and the paucity of
cross-disciplinary relationships (38%) and workforce
education (29%).
Focused workshop discussions
How can we provide equitable gene testing to ovarian cancer
patients and their families?
All of the cancer genetic centre representatives were in
full agreement that provision and access to gene testing
for ovarian cancer patients needs to be improved. Many
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gene testing within the gynae-oncology services, with
close liaison and support from genetics. The discussion
highlighted significant challenges to this approach, most
immediately education and funding. It was agreed that
successful integration of cancer gene testing into oncol-
ogy services would require consistent, clear, user-friendly
guidelines to ensure high-quality, robust, equitable care
pathways. The importance of ensuring the expertise of
cancer genetic services was fully utilised in the devel-
opment and implementation of increased testing for
ovarian cancer patients across the UK was particularly
highlighted.
How can we ensure variants are interpreted and managed
appropriately?
Sequencing of a gene, by any method, will identify se-
quence variants, many of which will alter the amino acid
sequence of the resulting protein. Thus clinical genetic
services are familiar with the need to interpret genetic
variants. However, there is little formal educational or
professional support for clinicians in the interpretation
and clinical management of variants, and decisions are
based on individual ‘expert’ opinion and experience. Fur-
thermore, for most cancer predisposition genes there are
no validated functional assays or computational tools
that can robustly predict the clinical impact of most
variants [16]. The consultation group identified that the
current specialist genetic workforce were not adequately
trained or supported in the clinical interpretation of
variants. Together with the absence of guidance for the
systematic clinical interpretation of variants, this has
resulted in inconsistencies in approaches to both test
reporting and variant management in the UK.
Reliance on individual expert opinion is not scalable
and its limitations will be magnified with increased can-
cer gene testing and the subsequent increased volume of
data to be interpreted. The consultation group discussed
the imperative for national consistency in reporting and
interpretation of variants, which should include clear
information about the clinical relevance and should be
readily triaged into management recommendations. The
growing momentum for mainstream (non-genetic) speciality
consultants to order gene tests places further urgency on
the development of robust, professionally agreed, national,
standardised systems of reporting, to ensure variants are
interpreted and managed consistently and appropriately.
How can we implement consistent cancer genetic care
across the UK?
It was agreed that consistency of care should be a central
tenet of the NHS cancer genetic services. It was recog-
nised that there is an existing need for improved
consistency of service delivery, methods for calculatingtest eligibility and risk thresholds, and patient and variant
management. There should be uniformity within and be-
tween genetic centres and this should also extend to gen-
etic care delivered outside the specialist genetic centres,
as increased mainstreamed testing evolves. To promote
and facilitate this there is a need for nationally agreed
standardised guidelines that are evidence-based and sim-
ple to understand.
While the consultation group acknowledged that there
will always be complex cases that fall outside of guid-
ance, they agreed that protocols would be able to guide
care for the majority of patients. Specific challenges
identified that can impede delivery of consistent genetic
care include the rapid evolution of the field, frequent
guideline updates and insufficient funding available to
enable successful and consistent implementation of guide-
lines into clinical practice nationally.
Conclusions
With the rapidly expanding knowledge of how genetics
can impact health and disease, there is a need for genetic
medicine to be more widely available [17]. Moreover,
improvements in the speed and affordability of DNA
sequencing have opened up enormous opportunities, in
numerous areas of medicine, to improve healthcare. It is
generally acknowledged that there is insufficient capacity
for specialist clinical geneticists to provide the genetic
elements of clinical care for all patients in all clinical
areas, either to meet current or future demand. It has
been proposed that ‘mainstreaming’ of genetic services
with incorporation of many aspects of genetic medicine
into the care pathways of other medical specialities is
the best solution [12,18,19]. However, movement towards
this model has been slow.
Cancer genetics is one of the foremost areas where
gene testing can impact healthcare. Cancer gene testing
is becoming increasingly relevant to the healthcare needs
of oncology patients impacting on diagnosis, manage-
ment and prognosis as well as having potential to
improve cancer risk information for their relatives.
Consultation with the UK cancer genetic services re-
ported here demonstrates the increasing demand from
clinicians and patients across the UK for cancer gene
testing. The key recommendations from the day are
outlined below.
There was consensus that the current system of gene
testing, which is largely restricted to patients seen by
specialist cancer genetic services, does not have capacity
to accommodate the increasing demand for cancer gene
testing. There was broad, though not universal, support
for mainstreaming of gene testing, that is, integration of
testing into routine patient pathways in oncology in
close liaison with genetic services. It was felt this would
likely prove the optimal pathway for most cancer
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would be required and close liaison with genetics, who
should continue see all patients found to have a muta-
tion or unclassified variant and any complex cases, was
felt essential.
Consistency of care should be a central tenet of both
the cancer genetic services and any future mainstreamed
gene testing within oncology. The most robust method
for achieving this will be through nationally agreed
evidence-based guidelines. It is essential that such guide-
lines are designed to easily allow iterative review and
incorporation of up-to-date evidence in this fast-moving
field of medicine.
The key challenges identified are summarised below.
The greatest concern to those working within the cancer
genetic services is in relation to the clinical interpret-
ation and management of genetic variants. There is an
existing urgent need for systematic guidance to aid the
consistent clinical interpretation of variants. In the near
future the volume of variants requiring interpretation
will greatly increase as the data being generated across
the healthcare sector are increasing rapidly through
increased single gene, panel, exome and whole genome
testing [12,20,21]. Accurate and reliable clinical inter-
pretation of this large volume of data will be required
for the full clinical utility of genomic medicine to be
realised [20,22]. Automated, systematic, evidence-based
variant interpretation guidelines/pipelines that can routinely
address 90% to 95% of variants will be required for integra-
tion of genomic medicine with mainstream specialties. Such
a system must also be dynamically responsive to new evi-
dence [22,23]. The remaining 5% to 10% of more complex
variants/cases will likely continue to require expert inter-
pretation by specialists.
Sufficient funding and appropriate resource allocation
are key challenges. Realising a healthcare system where
genetic information is integrated in standard medical care
is a complex task that will require sustained effort and
resources within organisational structures receptive to
change [17]. Commissioning is a key mechanism for deliv-
ering equitable high quality services that incorporate genet-
ics and genomics across the UK. The system of specialist
commissioning, in which clinical genetics is currently
housed, seems at odds with a model of ‘mainstreaming’ for
service delivery. This clear disjunction between ‘specialised’
commissioning and delivery of ‘mainstreamed’ services will
ultimately demand a novel approach to resource allocation
in order to incorporate a growing volume of gene testing
within the healthcare service as a whole.
In the genetics white paper the government stated its
ambition for a ‘National Health Service to incorporate
genetics in every sector’, although how this is to be
achieved remains unclear [1]. The implementation of
genomic medicine within the NHS is an ambition thatdemands action and operational leadership beyond rhet-
oric. Building on the insights from the cancer genetic
services consultation day the MCG programme is opti-
mising and evaluating a ‘mainstream’ model of gene test-
ing whereby the test in cancer patients is performed
within cancer services, underpinned by the expert sup-
port of genetics. Additional priorities will be to develop
systematic approaches for the clinical interpretation of
large-scale genetic data that will result from adoption of
genomic medicine.
Key recommendations
1. Mainstreaming of cancer gene testing, with tests in
cancer patients performed through the routine cancer
patient pathway, is likely to be the optimal approach to
deliver the required volume of tests.
2. Mainstreaming should be implemented in collaboration
with genetics, who should continue to see any individuals
found to have mutations, and any complex cases.
3. Nationally agreed, evidence-based, simple guidelines
outlining eligibility for gene testing are required to
ensure national consistency.
4. Consistent clinical interpretation of variants is
required. Improved training and support for
geneticists in clinical variant interpretation together
with improved automated interpretation pipelines
should be developed.
5. A sustainable model of resource allocation that
promotes and supports this mainstreamed model of
service delivery is required.
Key challenges identified
1. Lack of capacity of cancer genetic services at a time
of greatly increased demand for cancer gene testing
from patients and clinicians.
2. Inconsistency of services and patient management,
particularly with regard to testing eligibility, risk
estimation and variant interpretation practices.
3. Education of non-geneticists to ensure appropriate
information and support is provided to the patients
they test.
4. Improved education of genetic services in clinical
interpretation and management of genetic variants.
5. Sufficient and appropriately configured funding.
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